At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 315 enrolled
Drug / intervention
Atogepant 60 mg +1 moredrug
Likely dose
Atogepant 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants With Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE)
In Brief
A Phase 3 clinical trial evaluating Atogepant 60 mg and Placebo for Episodic Migraine. Completed, enrolled 315 participants across 114 sites in 15 countries.
Detailed Summary
This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesAustralia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMar 2021
Primary CompletionAug 2022
TodayJul 2026
First PostedFeb 5, 2021
Enrollment StartMar 5, 2021
Primary CompletionAug 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago
Interventions
Atogepant 60 mgdrug
Atogepant tablets.
Placebodrug
Atogepant matching placebo tablets.